01 — At a Glance
The Pharma Giant That Just Turned Serious About Specialty Care
- 52-Week High / Low₹2,370 / ₹1,774
- Q3 FY26 Revenue₹7,168 Cr
- Q3 FY26 PAT₹1,181 Cr
- Q3 EPS (₹)₹25.73
- Annualised EPS (9M Avg×4)₹102.2
- Book Value₹430
- Price to Book5.45x
- Dividend Yield0.51%
- Debt / Equity0.32x
- Return (6 months)+20.4%
Auditor’s Opening Note: Lupin closed Q3 FY26 with ₹7,168 crore revenue (+24.3% YoY), ₹1,181 crore PAT (+75.99% YoY), and a profit jump of 76%. EBITDA margin expanded to 31.1% — call it the highest the company has ever been. Meanwhile, the US business touched USD 350 million quarterly (highest-ever), Pegfilgrastim (biosimilar) just got FDA approval, and a ₹2,000 crore ophthalmic company acquisition is about to close. The P/E of 21.5x is justified if they execute specialty right. The P/E becomes expensive if they don’t.
02 — Introduction
The Generic Drugmaker That Wants to Be a Specialty Pharma Legend
Once upon a time, Lupin was a name that appeared on generic blister packs and government tender lists. Respectable. Profitable. Boring. The kind of pharmaceutical company that sells amoxicillin at ₹2 per tablet and calls it innovation.
No longer. Management’s Q3 concall sounded like someone who finally got bored with the generic game and decided to play specialty poker. Biosimilars launching. Injectables ramping. Ophthalmic footprint expanding into Europe. GLP-1 diabetes plays (yes, the obesity drug thing). And a pivot to 505(b)(2) complex generics that actually command pricing power. The company is still selling generics in India and the US — it’s not going anywhere — but the future is being architected in specialty clinics, oncology units, and data centre cooling facilities (seriously, they mentioned that).
Q3 FY26 was the inflection point. The results prove it. And the stock market has finally started noticing. But here’s the question: Is Lupin about to become a growth story with real legs, or just another generic pharma company dressed up in specialty clothing with a loan on its balance sheet?
Let’s find out. With data, some sarcasm, and the kind of granular commentary that usually requires a ₹2 lakh annual subscription to actual research houses.
Concall Highlight (Feb 2026): “Highest sales ever in the US” + “exceed[ed] the record performance we had delivered last quarter” = management is literally on an adrenaline drip. This is the tone of executives who have finally seen their strategy work.
03 — Business Model: WTF Do They Even Do?
Generics (The Old Reliable). Plus Biosimilars (The New Sexy). Plus Everything In Between.
Lupin is an integrated pharmaceutical company operating across three segments: formulations (95% of revenue), APIs (5% of revenue), and an increasingly strategic division in biosimilars. Geographically, they earn 38% from the US, 34% from India, 13% from developed markets (Europe, Canada, Australia), and 11% from emerging markets (Brazil, South Africa, Latin America, Philippines).
The US business is their cash cow. They’re the third-largest generic pharma company by prescription volume in America. That means billions of pills moving through American pharmacies under their label every year. Tolvaptan (cystic fibrosis), Mirabegron (bladder), Arfomoterol (asthma) — these are Lupin generics that doctors prescribe and patients don’t even realize who made them.
India is where they own retail relationships. 8 brands in the top 300 selling products nationally. Ranks sixth by sales. Strength in cardiovascular, respiratory, diabetes, and anti-infectives. The moat here is distribution intensity — they have 11,000+ medical representatives on the ground, just added 900 in the last six months.
But the real story now is what’s coming: Biosimilars, Injectables, and 505(b)(2) complex generics. These command better margins, longer exclusivity windows, and pricing power. Pegfilgrastim (Lupin’s first US biosimilar, just approved) could generate meaningful revenue in FY27. Ranibizumab (eye drug) launches in FY27. And injectables are targeted at USD 100 million+ in three years. The generic pharma treadmill is still humming. The specialty pharmacy machine is just now warming up.
US Market Rank3rdBy Prescriptions
India Market Rank6thBy Sales
Geographic Mix38% US34% India
R&D Intensity7.5%of FY26 sales
Biosimilar Inflection: “A couple of years ago, we were not very gung-ho on biosimilars, but today we see significant potential,” management said in the concall. Translation: we finally stopped being scared of the regulatory complexity and realized we’re the only truly integrated player with India cost advantage. Pegfilgrastim + Ranibizumab + Aflibercept could be ~USD 100m in revenue in 2–3 years.
💬 Are you betting on Lupin to become the next specialty pharma story, or are you still seeing a generic drugmaker in fancy clothing? Drop your hot take!
04 — Financials Overview
Q3 FY26: The Numbers That Changed Everything
Result type: Quarterly Results | Q3 FY26 EPS: ₹25.73 | 9M FY26 Avg EPS (×4): ₹102.2 | FY25 Full-Year EPS: ₹71.88
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 7,168 | 5,768 | 7,048 | +24.3% | +1.7% |
| EBITDA | 2,230 | 1,755 | 1,948 | +27.1% | +14.5% |
| EBITDA Margin % | 31.1% | 30.4% | 27.6% | +70 bps | +350 bps |
| PAT | 1,181 | 673 | 1,102 | +75.5% | +7.2% |
| EPS (₹) | 25.73 | 14.71 | 24.06 | +75.0% | +6.9% |
The Details Matter: Q3 PAT jumped 76% YoY. Sounds insane. But wait — one-time items matter. There’s a USD 90 million settlement from Astellas (Mirabegron patent case). USD 50 million antitrust provision. INR 8,200 crore divestment gain from an OTC business sale. Strip those out, underlying operational profit is still +40–45% YoY. Still fantastic. Just not “too good to be true” fantastic. EBITDA margin at 31.1% is highest ever. Gross margin expanded 420 bps YoY to 73.5% — driven by better product mix, lower in-licensed products, and cost efficiencies. But management expects Q4 margin to be “tempered” by higher R&D spend and lower PLI income. FY26 margin guidance: 27–28%. FY27: conservative 24–25%.
05 — Valuation Discussion: Fair Value Range
What’s This Specialty Pharma Transformation Actually Worth?
Join 10,000+ investors who read this every week.
